ALAUNOS THERAPEUTICS INC (TCRT) Stock Income Statement
NASDAQ:TCRT - Nasdaq - US98973P3091 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00K | 5.00K | 2.92M | 398.00K | 0.00 | |||
| Operating Expenses | 4.82M | 28.50M | 38.16M | 73.55M | 80.36M | |||
| Research and Development | 362.00K | 16.28M | 25.02M | 47.27M | 52.70M | |||
| Selling, General, and Administrative Expenses | 4.46M | 12.22M | 13.14M | 26.27M | 27.66M | |||
| Operating Income | -4.81M | -28.49M | -35.24M | -73.15M | -80.36M | |||
| Interest Income/Expense | 0.00 | -1.92M | -3.15M | -1.18M | N/A | |||
| Other Income/Expense | 133.00K | 1.05M | 529.00K | -20.00K | 385.00K | |||
| Non Recurring Items | 0.00 | -5.77M | 133.00K | -4.40M | N/A | |||
| Income Before Taxes | -4.68M | -35.14M | -37.73M | -78.75M | -79.98M | |||
| Net Income | -4.68M | -35.14M | -37.73M | -78.75M | -79.98M | |||
| EBITDA | -4.81M | -26.18M | -32.48M | -70.56M | -79.23M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.92 | -2.20 | -2.61 | -5.51 | -5.72 | |||
| Non GAAP EPS | N/A | -22.90 | -27.00 | -55.50 | -58.50 | |||
| Statistics | ||||||||
| Profit Margin | -46790.00% | -702800.00% | -1291.24% | -19786.68% | N/A | |||
| Operating Profit Margin | -48120.00% | -569860.00% | -1205.95% | -18379.90% | N/A | |||
All data in USD